Colorectal cancer

Active Ingredient: Irinotecan

Indication for Irinotecan

Population group: only adults (18 years old or older)

Irinotecan is indicated for the treatment of patients with advanced colorectal cancer:

  • in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease,
  • as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.

Irinotecan in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy.

Irinotecan in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Irinotecan in combination with capecitabine with or without bevacizumab is indicated for first-line treatment of patients with metastatic colorectal carcinoma.

For this indication, competent medicine agencies globally authorize below treatments:

180-350 mg/m² once every 2-3 weeks

Route of admnistration

Intravenous

Defined daily dose

180 - 350 mg per m² of body surface area (BSA)

Dosage regimen

From 180 To 350 mg per m² of body surface area (BSA) once every 21 day(s)

Detailed description

In monotherapy (for previously treated patient): The recommended dosage of irinotecan is 350 mg/m² administered as an intravenous infusion over a 30- to 90-minute period every three weeks.

In combination therapy (for previously untreated patient): Safety and efficacy of irinotecan in combination with 5-fluorouracil (5FU) and folinic acid (FA) have been assessed with the following schedule.

Irinotecan plus 5FU/FA in every 2 weeks schedule

The recommended dose of irinotecan is 180 mg/m² administered once every 2 weeks as an intravenous infusion over a 30- to 90-minute period, followed by infusion with folinic acid and 5 fluorouracil.

Normally, the same dose of irinotecan is used as administered in the last cycles of the prior irinotecan-containing regimen. Irinotecan must not be administered earlier than 1 hour after the end of the cetuximab infusion.

Dosage considerations

Intravenous infusion over a 30- to 90- minute period.

Active ingredient

Irinotecan

Irinotecan is a semi-synthetic derivative of camptothecin. It is an antineoplastic agent which acts as a specific inhibitor of DNA topoisomerase I.

Read more about Irinotecan

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.